PDS Biotechnology Corporation
PDSB
Positions held
Your positionsPDSB isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $89.87M | Enterprise value | $55.86M | Trailing P/E | — | Forward P/E | -3.59 |
| PEG | — | Price / book | -19.38 | Beta | 1.17 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -5.4% | ROA | -70.6% | Debt / equity | — |
| Current ratio | 0.57 | Free cash flow | -$13.76M | Analyst recommendation | strong_buy | Mean target | $5.00 |
| 52w high | $1.55 | 52w low | $0.20 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$9.8M | -$7.3M | -$7.6M | -$9.0M | -$9.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.5M | -$6.5M | -$6.7M | -$8.1M | -$7.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$34.5M | -$37.6M | -$42.9M | -$40.9M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$31.5M | -$36.3M | -$43.0M | -$41.7M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · BC-Most Active Stocks
2026-09-29 · KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
2026-09-18 · PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny
2026-09-18 · ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?
2026-09-17 · This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rally
2026-09-16 · BC-Most Active Stocks
2026-09-15 · BC-Most Active Stocks
2026-09-14 · IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet
2026-09-14 · PDS Biotechnology Reports Initial Closing of Private Financing
2026-09-14 · BC-Most Active Stocks
Price (daily)
Full chart · RSI · MACD · patterns